Nippon India PHARMA Fund - G

NAV ₹260.988 ↑ 0.88 (0.34 %) as on 24 Jun 22

Table of Contents

Scheme Objective
NAV Price Chart
Returns
- Historical Returns
- Compounded Returns
Growth Of 10k Over Years
Holdings / Portfolio
All Plan & Options
Fund Manager Information
Custodians
Registrar & Transfer Agent (RTA)
Administrator Companies
Auditors

Scheme Objective

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

Nippon India Pharma Fund is a Equity - Sectoral fund launched on 5 Jun 04. It is a fund with High risk and has given a CAGR return of 19.8% since its launch. Ranked 35 in Sectoral category. Return for 2021 was 23.9% , 2020 was 66.4% and 2019 was 1.7% .

Below is the key information for Nippon India Pharma Fund

NAV as on 24 Jun 22	₹260.988 ↑ 0.88 (0.34 %)
Net Assets (AUM) as on 31 May 2022	₹4,516 Cr.
Launch Date	5 Jun 2004
Category	Equity - Sectoral
Rating	☆☆
Type	Open Ended Fund
Risk	High
AMC	Nippon Life Asset Management Ltd.

Alpha Ratio	-1.22
Expense Ratio	0.96 %
Sharpe Ratio	-0.797
Information Ratio	0.68
Benchmark	Not Available
Min Investment	₹5,000
Min SIP Investment	₹100
Exit Load	0-1 Years (1%),1 Years and above(NIL)

NAV Price Chart

Returns

Annual Compounded Returns

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 24 Jun 22

Duration	Returns
1 Month	-1.7%
3 Month	-10.3%
6 Month	-12.2%
1 Year	-12.4%
3 Year	23.3%
5 Year	15.5%
10 Year
15 Year
Since launch	19.8%

Historical Annual Returns

Historical performance (Yearly) on absolute basis

Year	Returns
2021	23.9%
2020	66.4%
2019	1.7%
2018	3.6%
2017	7.6%
2016	-10.6%
2015	19.4%
2014	49.5%
2013	20.9%

Growth of 10k Over Years

Date	Value
31 May 17	₹10,000
31 May 18	₹11,117
31 May 19	₹11,853
31 May 20	₹15,327
31 May 21	₹24,063
31 May 22	₹22,001

Nippon India PHARMA Fund Growth 10k Chart

Asset Allocation

Asset Class	Value
Cash	1.33%
Equity	98.67%

Sector Allocation

Sector	Value
Health Care	98.17%

Nippon India PHARMA Fund Equity Allocation

Top Securities Holdings / Portfolio

Holdings/Securities

Name	Global Industry	Holding	Value	Quantity
Sun Pharmaceuticals Industries Ltd (Healthcare) Equity, Since 31 Oct 09 \| SUNPHARMA	Drug Manufacturers - Specialty & Generic	14%	₹678 Cr	7,300,976
Cipla Ltd (Healthcare) Equity, Since 31 May 08 \| CIPLA	Drug Manufacturers - General	8%	₹412 Cr	4,200,000
Divi's Laboratories Ltd (Healthcare) Equity, Since 31 Mar 12 \| DIVISLAB	Drug Manufacturers - Specialty & Generic	8%	₹383 Cr	850,000
Dr Reddy's Laboratories Ltd (Healthcare) Equity, Since 30 Jun 11 \| DRREDDY	Drug Manufacturers - Specialty & Generic	7%	₹355 Cr	858,077
Lupin Ltd (Healthcare) Equity, Since 31 Aug 08 \| LUPIN	Drug Manufacturers - Specialty & Generic	7%	₹320 Cr	4,300,025
Torrent Pharmaceuticals Ltd (Healthcare) Equity, Since 30 Sep 20 \| TORNTPHARM	Drug Manufacturers - Specialty & Generic	6%	₹298 Cr	1,057,600
Narayana Hrudayalaya Ltd (Healthcare) Equity, Since 30 Jun 17 \| NH	Medical Care Facilities	6%	₹290 Cr	4,142,057 ↓ -220,567
Abbott India Ltd (Healthcare) Equity, Since 31 May 11 \| ABBOTINDIA	Drug Manufacturers - General	5%	₹243 Cr	142,537
Aurobindo Pharma Ltd (Healthcare) Equity, Since 31 Dec 15 \| AUROPHARMA	Drug Manufacturers - Specialty & Generic	5%	₹220 Cr	3,500,000
Fortis Healthcare Ltd (Healthcare) Equity, Since 31 Aug 18 \| FORTIS	Medical Care Facilities	4%	₹183 Cr	6,840,000

1 - 10 of 30

Ready to Invest?
Talk to our investment specialist

Fund Managers

Name	Since	Tenure
Sailesh Raj Bhan	1 Apr 05	17.18 Yr.
Kinjal Desai	25 May 18	4.02 Yr.

Custodians

Company	Address
Deutsche Bank AG	Deutsche Bank AG,Kodak House, 22, D.N. Road,

Registrar & Transfer Agent

KFin Technologies Limited
Address	KFin Technologies Pvt. Ltd,,1D/D Extension 2, Valmiki Chowk,,Gandhi Nagar,
FAX	91-40-23311968
Email	mailmanager@karvy.com

Administrator Companies

Company	Address
Nippon India Mutual Fund	9th Floor, Crescenzo, C-38 & 39,,G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400051

Auditors

Company	Address
Haribhakti & Co. Chartered Accountants	42, Free Press House,4th Floor,,215, Nariman Point,

All Plan & Options

Fund and Plan	NAV	6 Month	1 Year	3 Year	5 Year
Nippon India Pharma Fund Normal Dividend, Payout	₹72.4715 ↑ 0.24	-8.34 %	-8.54 %	27.84 %	17.78 %
Nippon India Pharma Fund Normal Dividend, Reinvestment	₹72.4715 ↑ 0.24	-8.34 %	-8.54 %	27.84 %	17.78 %
Nippon India Pharma Fund Growth	₹260.988 ↑ 0.88	-12.17 %	-12.37 %	23.29 %	15.49 %
Data as on 24 Jun 22

Disclaimer:
All efforts have been made to ensure the information provided here is accurate. However, no guarantees are made regarding correctness of data.

Shepard Technologies Pvt. Ltd : A -204, Technocity, Plot No X-4/1 & X-4/2, TTC, MIDC, Mahape, Navi Mumbai - 400710

AMFI Registration No. 112358 | CIN: U74999MH2016PTC282153

Mutual fund investments are subject to market risks. Please read the scheme information and other related documents carefully before investing. Past performance is not indicative of future returns. Please consider your specific investment requirements before choosing a fund, or designing a portfolio that suits your needs.

Shepard Technologies Pvt. Ltd. (with ARN code 112358) makes no warranties or representations, express or implied, on products offered through the platform. It accepts no liability for any damages or losses, however caused, in connection with the use of, or on the reliance of its product or related services. Terms and conditions of the website are applicable.